New oral drug tested for Hard-to-Treat cancers with specific genetic flaw
Disease control
Ongoing
This early-stage study is testing a new oral medication called APS03118 in adults with advanced solid tumors that have specific RET genetic changes. The main goals are to find a safe dose, see how the body processes the drug, and get an initial look at whether it helps control th…
Phase: PHASE1 • Sponsor: Applied Pharmaceutical Science, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC